Atopic Keratoconjunctivitis (AKC)


Atopic Keratoconjunctivitis (AKC) or Atopic Dermatitis Patients

Study Status

Icon for study status

Currently Enrolling

Study Length

Icon for 7 visits

This study involves 7 visits over the course of approximately 18 weeks. You may also have the option to continue in the study for an additional 4 visits.


Icon for compensation of up to $945 to 1485 for 7 to 11 visits

If you complete all 7 visits, you will be compensated $945 for your time. If you complete all 11 visits, you will be compensated $1,485 for your time. If you do not qualify to complete all of the visits, you will be paid for each visit that you come into the office for.

Current Locations

Icon for current locations

Andover, MA
Smyrna, TN
Shelby, NC
Kansas City, MO
Great Neck, NY
Bala Cynwyd, PA
Littleton, CO
Los Angeles, CA
Hollywood, FL
Ann Arbor, MI
Round Rock, TX
Springfield, MO
Hawthorne, NY

Upcoming Locations

Icon for upcoming locations

We are adding new locations for this study regularly. Please fill out the form below to learn more.

General study information

This study is intended for people who have signs and symptoms of Atopic Keratoconjunctivitis (AKC). Common symptoms of AKC are red, burning or itchy eyes and excessive tearing or sensitivity to light.

The purpose of this study is to evaluate how effective subcutaneous injections or “shots” (applied under the skin) of an investigational drug are compared to placebo (drug without the active ingredient) for the treatment of the signs and symptoms of AKC.

Contact us and see if this study is right for you

Key requirements

Key Inclusion Criteria

  • Be at least 18 years old.
  • Have a history or diagnosis of AKC or atopic dermatitis (eczema).

Key Exclusion Criteria

  • No contact lenses within 48 hours of the study and for the duration of the study.
  • Have had any previous exposure to Dupixent®.

Email moving fast icon

Receive Trial Alerts

Sign up for email alerts when new trials and locations are added for a medical condition.